The Role of Aryl Hydrocarbon Receptor in the Pathogenesis and Treatment of Psoriasis.
| Autor: | Lin X; Department of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, China., Meng X; Department of Pathology and Laboratory Medicine, Axia Women's Health, Oaks, PA, USA., Lin J; Department of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of cutaneous medicine and surgery [J Cutan Med Surg] 2024 May-Jun; Vol. 28 (3), pp. 276-286. Date of Electronic Publication: 2024 Mar 18. |
| DOI: | 10.1177/12034754241239050 |
| Abstrakt: | The pathogenesis of psoriasis is complex. Aryl hydrocarbon receptor (AhR) is a transcription factor that can be bound and activated by structurally diverse ligands and plays an important role in a range of biological processes and in the pathogenesis of different diseases. Recently, the role of AhR in psoriasis has attracted attention. AhR has toxicological functions and physiological functions. The overexpression and activation of AhR induced by the environmental pollutant and exogenous AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can drive the development of psoriasis. This TCDD-mediated toxicological response disrupts the physiological functions of AhR resulting in skin barrier disorders and the release of inflammatory cytokines, 2 of the pivotal factors of psoriasis. In addition, highly upregulated kynureninase in psoriasis decreases endogenous AhR agonists, thereby weakening the physiological functions of AhR. Activating AhR physiological signalling should be useful in the treatment of psoriasis. Studies have demonstrated that physiological activation of AhR can dampen the severity of psoriasis. The oldest and effective treatment for psoriasis coal tar works by activating AhR, and both new anti-psoriasis drugs tapinarof and benvitimod are formulations of AhR agonist, supporting that activation of AhR can be used as a new strategy for the treatment of psoriasis. Preclinical and preliminary clinical studies have revealed the anti-psoriasis effects of a number of AhR agonists, providing potential candidates for the development of new drugs for the treatment of psoriasis. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|